Studying rare genetic variations in prostate cancer using diverse genetic data
Leveraging whole-exome sequence data from diverse biobanks and cohorts to study rare coding variation in prostate cancer
This study is looking at how certain rare genetic changes might increase the risk of prostate cancer, using data from different groups of people, to help doctors better understand and treat the disease for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-10932197 on NIH RePORTER |
What this research studies
This research investigates the genetic factors contributing to prostate cancer by analyzing whole-exome and whole-genome sequencing data from various biobanks and cohorts. The study aims to identify rare genetic variations that may increase the risk of developing prostate cancer, particularly focusing on low-frequency alleles that are often overlooked. By integrating data from multiple ancestries, the research seeks to provide a comprehensive understanding of how these rare variations affect prostate cancer susceptibility and aggressiveness. Patients may benefit from insights that could lead to improved risk assessment and personalized treatment options based on their genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research include men with a family history of prostate cancer or those from diverse ancestral backgrounds who may carry rare genetic variations.
Not a fit: Patients without a family history of prostate cancer or those who do not belong to the targeted ancestral groups may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and management of prostate cancer risk, potentially improving outcomes for patients.
How similar studies have performed: Previous research has shown promise in identifying genetic variations linked to cancer risk, suggesting that this approach could yield valuable insights.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Haiman, Christopher Alan — University of Southern California
- Study coordinator: Haiman, Christopher Alan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.